Olaf Wittenstein1, Fabian Krause2, Mirko Fischer3, Justus Domschikowski2, Mirko Nitsche4, Christoph Henkenberens3, Daniel Habermehl5, Juergen Dunst2. 1. Department of Radiation Oncology, Universitätsklinikum Schleswig-Holstein Campus Kiel, Arnold-Heller-Straße 3, Haus L, 24105, Kiel, Germany. olaf.wittenstein@uksh.de. 2. Department of Radiation Oncology, Universitätsklinikum Schleswig-Holstein Campus Kiel, Arnold-Heller-Straße 3, Haus L, 24105, Kiel, Germany. 3. Department of Radiotherapy and Special Oncology, Medical School Hannover, Hannover, Germany. 4. Center for Radiotherapy and Radio-oncology Bremen and Westerstede, 28239, Bremen, Germany. 5. Radprax MVZ, Leimbacher Str. 51a, 42281, Wuppertal, Germany.
Abstract
PURPOSE: For patients with large tumors palliative radiotherapy often is the only local treatment option. To prevent toxicity the administered doses are low. Dose escalation to the tumor could be an option to better smyptom control and prolong local control rates. In this prospective study we used a very pragmatic approach with a simultaneously integrated boost (SIB) to an almost geometrically defined tumor core to achieve this. The primary endpoint was to demonstrate feasibility. METHOD: Patients with solid tumors > 4 cm in diameter of different histologies were eligible in this single arm, prospective, multi-institutional clinical feasibility trial with two treatment concepts: 5 × 5 Gy with an integrated boost to the tumor core of 5 × 10 Gy or 10 × 3 Gy with a boost of 10 × 6 Gy. The objective of dose escalation in this study was to deliver a minimum dose of 150% of the prescribed dose to the gross tumor volume (GTV) tumor core and to reach a maximum of at least 200% in the tumor core. RESULTS: In all, 21 patients at three study sites were recruited between January 2019 and November 2020 and were almost evenly spread (9 to 12) between the two concepts. The treated planning target volumes (PTV) averaged 389.42 cm3 (range 49.4-1179.6 cm3). The corresponding core volumes were 72.85 cm3 on average (range 4.21-338.3 cm3). Dose escalation to the tumor core with mean doses of 167.7-207.7% related to the nonboost prescribed isodose led to PTV mean doses of 120.5-163.3%. Treatment delivery and short-term follow-up was successful in all patients. CONCLUSIONS: Palliative radiotherapy with SIB to the tumor core seems to be a feasible and well-tolerated treatment concept for large tumors. The applied high doses of up to 50 Gy in 5 fractions (or 60 Gy in 10 fractions) did not cause unexpected side effects in the 42 day follow-up period. Further research is needed for more information on efficacy and long-term toxicity.
PURPOSE: For patients with large tumors palliative radiotherapy often is the only local treatment option. To prevent toxicity the administered doses are low. Dose escalation to the tumor could be an option to better smyptom control and prolong local control rates. In this prospective study we used a very pragmatic approach with a simultaneously integrated boost (SIB) to an almost geometrically defined tumor core to achieve this. The primary endpoint was to demonstrate feasibility. METHOD: Patients with solid tumors > 4 cm in diameter of different histologies were eligible in this single arm, prospective, multi-institutional clinical feasibility trial with two treatment concepts: 5 × 5 Gy with an integrated boost to the tumor core of 5 × 10 Gy or 10 × 3 Gy with a boost of 10 × 6 Gy. The objective of dose escalation in this study was to deliver a minimum dose of 150% of the prescribed dose to the gross tumor volume (GTV) tumor core and to reach a maximum of at least 200% in the tumor core. RESULTS: In all, 21 patients at three study sites were recruited between January 2019 and November 2020 and were almost evenly spread (9 to 12) between the two concepts. The treated planning target volumes (PTV) averaged 389.42 cm3 (range 49.4-1179.6 cm3). The corresponding core volumes were 72.85 cm3 on average (range 4.21-338.3 cm3). Dose escalation to the tumor core with mean doses of 167.7-207.7% related to the nonboost prescribed isodose led to PTV mean doses of 120.5-163.3%. Treatment delivery and short-term follow-up was successful in all patients. CONCLUSIONS: Palliative radiotherapy with SIB to the tumor core seems to be a feasible and well-tolerated treatment concept for large tumors. The applied high doses of up to 50 Gy in 5 fractions (or 60 Gy in 10 fractions) did not cause unexpected side effects in the 42 day follow-up period. Further research is needed for more information on efficacy and long-term toxicity.
Authors: Stephen Lutz; Lawrence Berk; Eric Chang; Edward Chow; Carol Hahn; Peter Hoskin; David Howell; Andre Konski; Lisa Kachnic; Simon Lo; Arjun Sahgal; Larry Silverman; Charles von Gunten; Ehud Mendel; Andrew Vassil; Deborah Watkins Bruner; William Hartsell Journal: Int J Radiat Oncol Biol Phys Date: 2011-01-27 Impact factor: 7.038
Authors: Benjamin Moeller; Ehsan H Balagamwala; Aileen Chen; Kimberly M Creach; Giuseppe Giaccone; Matthew Koshy; Sandra Zaky; George Rodrigues Journal: Pract Radiat Oncol Date: 2018-04-04
Authors: E Steenland; J W Leer; H van Houwelingen; W J Post; W B van den Hout; J Kievit; H de Haes; H Martijn; B Oei; E Vonk; E van der Steen-Banasik; R G Wiggenraad; J Hoogenhout; C Wárlám-Rodenhuis; G van Tienhoven; R Wanders; J Pomp; M van Reijn; I van Mierlo; E Rutten; J Leer; T van Mierlo Journal: Radiother Oncol Date: 1999-08 Impact factor: 6.280
Authors: Susanne Stera; Panagiotis Balermpas; Mark K H Chan; Stefan Huttenlocher; Stefan Wurster; Christian Keller; Detlef Imhoff; Dirk Rades; Jürgen Dunst; Claus Rödel; Guido Hildebrandt; Oliver Blanck Journal: Strahlenther Onkol Date: 2017-09-05 Impact factor: 3.621
Authors: Jenny Capuccini; Gabriella Macchia; Eleonora Farina; Milly Buwenge; Domenico Genovesi; Luciana Caravatta; Nam P Nguyen; Silvia Cammelli; Savino Cilla; Tigeneh Wondemagegnhu; A F M Kamal Uddin; Mostafà Aziz Sumon; Francesco Cellini; Vincenzo Valentini; Francesco Deodato; Alessio G Morganti Journal: Clin Exp Metastasis Date: 2018-08-18 Impact factor: 5.150
Authors: Yvette M van der Linden; Elsbeth Steenland; Hans C van Houwelingen; Wendy J Post; Bing Oei; Corrie A M Marijnen; Jan Willem H Leer Journal: Radiother Oncol Date: 2006-03-20 Impact factor: 6.280
Authors: Michael R Folkert; Mark H Bilsky; Ashlyn K Tom; Jung Hun Oh; Kaled M Alektiar; Ilya Laufer; William D Tap; Yoshiya Yamada Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-01 Impact factor: 7.038
Authors: Matthias Guckenberger; Frederick Mantel; Peter C Gerszten; John C Flickinger; Arjun Sahgal; Daniel Létourneau; Inga S Grills; Maha Jawad; Daniel K Fahim; John H Shin; Brian Winey; Jason Sheehan; Ron Kersh Journal: Radiat Oncol Date: 2014-10-16 Impact factor: 3.481
Authors: Dirk Rades; Jon Cacicedo; Antonio J Conde-Moreno; Barbara Segedin; Darejan Lomidze; Raquel Ciervide; Niels H Hollaender; Steven E Schild Journal: Radiat Oncol Date: 2021-01-07 Impact factor: 3.481